@AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the @Région Auvergne-Rhône-Alpes, France, incorporated in March 2023 with the objective of developing a new class of sugar-based anti-infective biotherapeutics to fight (re)emerging infectious diseases.
Thanks to a Bioengineering plateform based on the expertise of the leading edge academic laboratory @CERMAV (@CNRS, @UGA, Grenoble, France), AIS Biotech aims to develop a pipeline of innovative sugar-based biopharmaceuticals which can prevent or treat infections by mimicking the natural host surface oligosaccharide binding-sites of pathogens.
GlycoFlu, our first drug-candidate validated at the preclinical stage by the #VirPath laboratory (@CIRI, @INSERM, @cnrs, @UCBL1, @ENS Lyon) and its Technology Research Platform @VirNext (@ucbl1), is developed to prevent or treat infections by human Influenza viruses, a global public health concern with a large socio-economic impact.
Company Details
- Employees
- 5
- Founded
- 2023
- Address
- Grenoble, 38000, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.ais-biotech.com
- Keywords
- des patients..
- HQ
- GRENOBLE
Ais Biotech Questions
Ais Biotech's website is http://www.ais-biotech.com
Ais Biotech's LinkedIn profile is https://fr.linkedin.com/company/ais-biotech
Ais Biotech has
5 employees.
View email and phone details for 5
employees at Ais Biotech.
Ais Biotech's industry is
Biotechnology Research
Ais Biotech's top competitors are
One Biosciences,
4moving Biotech,
Embobio Medical,
Alpioner Therapeutics,
The Element Biotechnology,
Cell&soft,
Methys Dx,
Dillico,
Acusurgical,
Pelican Health.
Ais Biotech's categories are Biotechnology Research
Ais Biotech's founding year is 2023
